KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Gross Profit (2016 - 2025)

Jazz Pharmaceuticals has reported Gross Profit over the past 16 years, most recently at $1.0 billion for Q4 2025.

  • Quarterly results put Gross Profit at $1.0 billion for Q4 2025, up 8.85% from a year ago — trailing twelve months through Dec 2025 was $3.9 billion (up 8.48% YoY), and the annual figure for FY2025 was $3.8 billion, up 3.89%.
  • Gross Profit for Q4 2025 was $1.0 billion at Jazz Pharmaceuticals, up from $997.2 million in the prior quarter.
  • Over the last five years, Gross Profit for JAZZ hit a ceiling of $1.0 billion in Q4 2025 and a floor of $567.4 million in Q1 2021.
  • Median Gross Profit over the past 5 years was $808.7 million (2022), compared with a mean of $829.8 million.
  • Biggest five-year swings in Gross Profit: grew 27.83% in 2022 and later grew 1.7% in 2025.
  • Jazz Pharmaceuticals' Gross Profit stood at $760.6 million in 2021, then rose by 5.81% to $804.8 million in 2022, then increased by 12.42% to $904.7 million in 2023, then rose by 6.05% to $959.5 million in 2024, then grew by 8.85% to $1.0 billion in 2025.
  • The last three reported values for Gross Profit were $1.0 billion (Q4 2025), $997.2 million (Q3 2025), and $929.4 million (Q2 2025) per Business Quant data.